Aethlon Medical (AEMD) Emerging Growth Conference 91 summary

Clinical trial overview

• Ongoing oncology trial in Australia targets patients with solid tumors unresponsive to anti-PD-1 immunotherapies like Keytruda or Opdivo.

• Study design includes three cohorts, each receiving increasing numbers of Hemopurifier (HP) treatments per week.

• Primary endpoint is safety, with additional focus on optimal HP treatment frequency and reduction of extracellular vesicles (EVs).

Recent developments and data

• Data Safety Monitoring Board (DSMB) reviewed cohort two and recommended advancing to the third and final cohort.

• Favorable trends in EV and immune cell numbers observed in the first cohort; cohort two data expected this quarter.

• Scientific rationale and study design published in BMJ Open.

Next steps and future outlook

• Enrollment for the third cohort is underway, with timing coordinated around patients' scheduled immunotherapy treatments.

• Aim to complete third cohort enrollment and data collection within the current quarter.

• Long-term goals include compiling data at the University of Sydney, submitting to Australian regulators, and planning a larger efficacy study based on safety findings.